Optimisation of replication-selective oncolytic adenoviral mutants in combination with chemotherapeutics

Journal of B.U.ON.

Volumn 14, Issue SUPPL.1, 2009, Pages

  Halldén, Gunnel ^a  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

Adenovirus; Apoptosis; Cytotoxic drugs; Oncolytic; Pancreas; Prostate

Indexed keywords

CASPASE 3; DOCETAXEL; FLUOROURACIL; GEMCITABINE; MITOXANTRONE; ONCOLYTIC ADENOVIRUS;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CELL KILLING; CONFERENCE PAPER; CONTROLLED STUDY; CYTOTOXICITY; DRUG POTENTIATION; E1ACR2 GENE; E1B19K GENE; ENZYME ACTIVATION; GENE; GENE DELETION; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PANCREAS CARCINOMA; PROSTATE CARCINOMA; TUMOR CELL; VIRUS REPLICATION;

ADENOVIRIDAE; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL LINE, TUMOR; COMBINED MODALITY THERAPY; DEOXYCYTIDINE; FLUOROURACIL; GENE THERAPY; HUMANS; MALE; MITOXANTRONE; NEOPLASMS; PANCREATIC NEOPLASMS; PROSTATIC NEOPLASMS; TAXOIDS; VIRUS REPLICATION;

EID: 70350076890     PISSN: 11070625     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (43)

1. Kasuya H, Takeda S, Nomoto S, Nakao A. The potential of oncolytic virus therapy for pancreatic cancer. Cancer Gene Ther 2005; 12: 725-736. (Pubitemid 41208612)
2. Parato KA, Senger D, Forsyth PA, Bell JC. Recent progress in the battle between oncolytic viruses and tumours. Nat Rev Cancer 2005; 5: 965-976. (Pubitemid 41766784)
3. Waehler R, Russell SJ, Curiel DT. Engineering targeted viral vectors for gene therapy. Nat Rev Genet 2007; 8: 573-587. (Pubitemid 47077278)
4. Matthews K, Noker PE, Tian B et al. Identifying the safety profile of Ad5.SSTR/TK.RGD, a novel infectivity-enhanced bicistronic adenovirus, in anticipation of a phase I clinical trial in patients with recurrent ovarian cancer. Clin Cancer Res 2009; 15: 4131-4137. (Pubitemid 46497925)
5. Aghi M, Martuza RL. Oncolytic viral therapies - the clinical experience. Oncogene 2005; 24: 7802-7816. (Pubitemid 41670681)
6. Liu TC, Galanis E, Kirn D. Clinical trial results with oncolytic virotherapy: a century of promise, a decade of progress. Nat Clin Pract Oncol 2007; 4: 101-117. (Pubitemid 46189539)
7. Nokisalmi PS, Escutenaire S, Ristimaki A et al. Clinical data from cancer patients treated with triple modified oncolytic adenovirus Ad5/3-Cox2L-D24. ESGCT; October 2008; Brugge, Belgium. Human Gene Therapy 19; 10: 1076.
8. Reid T, Warren R, Kirn D. Intravascular adenoviral agents in cancer patients: lessons from clinical trials. Cancer Gene Ther 2002; 9: 979-986. (Pubitemid 35462561)
9. Khuri FR, Nemunaitis J, Ganly I et al. A controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer. Nat Med 2000; 6: 879-885. (Pubitemid 30644745)
10. O'Shea CC, Johnson L, Bagus B et al. Late viral RNA export, rather than p53 inactivation, determines ONYX-015 tumor selectivity. Cancer Cell 2004; 6: 611-623. (Pubitemid 40017704)
11. Garber K. China approves world's first oncolytic virus therapy for cancer treatment. J Natl Cancer Inst 2006; 98: 298-300.
12. Hecht JR, Bedford R, Abbruzzese JL et al. A phase I/II trial of intratumoral endoscopic ultrasound injection of ONYX-015 with intravenous gemcitabine in unresectable pancreatic carcinoma. Clin Cancer Res 2003; 9: 555-561. (Pubitemid 36182584)
13. Xia ZJ, Chang JH, Zhang L et al. Phase III randomized clinical trial of intratumoral injection of E1B gene-deleted adenovirus (H101) combined with cisplatin-based chemotherapy in treating squamous cell cancer of head and neck or esophagus. Ai Zheng 2004; 23: 1666-1670.
14. Wang Y, Hallden G, Hill R et al. E3 gene manipulations affect oncolytic adenovirus activity in immunocompetent tumor models. Nat Biotechnol 2003; 21: 1328-1335. (Pubitemid 37356618)
15. Fulci G, Dmitrieva N, Gianni D et al. Depletion of peripheral macrophages and brain microglia increases brain tumor titers of oncolytic viruses. Cancer Res 2007; 67: 9398-9406. (Pubitemid 47535930)
16. Heise C, Hermiston T, Johnson L et al. An adenovirus E1A mutant that demonstrates potent and selective systemic anti- tumoral efficacy. Nat Med 2000; 6: 1134-1139. (Pubitemid 30792193)
17. Page JG, Tian B, Schweikart K et al. Identifying the safety profile of a novel infectivity-enhanced conditionally replicative adenovirus, Ad5-delta24-RGD, in anticipation of a phase I trial for recurrent ovarian cancer. Am J Obstet Gynecol 2007; 196: 389 e1-9; discussion e9-10. (Pubitemid 46497925)
18. Stolarek R, Gomez-Manzano C, Jiang H, Suttle G, Lemoine MG, Fueyo J. Robust infectivity and replication of Delta-24 adenovirus induce cell death in human medulloblastoma. Cancer Gene Ther 2004; 11: 713-720. (Pubitemid 39488469)
19. Small EJ, Carducci MA, Burke JM et al. A phase I trial of intravenous CG7870, a replication-selective, prostate-specific antigen-targeted oncolytic adenovirus, for the treatment of hormone-refractory, metastatic prostate cancer. Mol Ther 2006; 14: 107-117.
20. DeWeese TL, van der Poel H, Li S et al. A phase I trial of CV706, a replication-competent, PSA-selective oncolytic adenovirus, for the treatment of locally recurrent prostate cancer following radiation therapy. Cancer Res 2001; 61: 7464-7472. (Pubitemid 32995035)
21. Barton KN, Stricker H, Brown SL et al. Phase I study of noninvasive imaging of adenovirus-mediated gene expression in the human prostate. Mol Ther 2008; 16: 1761-1769.
22. Freytag SO, Stricker H, Peabody J et al. Five-year follow-up of trial of replication-competent adenovirus-mediated suicide gene therapy for treatment of prostate cancer. Mol Ther 2007; 15: 636-642. (Pubitemid 46306608)
23. Freytag SO, Movsas B, Aref I et al. Phase I trial of replication- competent adenovirus-mediated suicide gene therapy combined with IMRT for prostate cancer. Mol Ther 2007; 15: 1016-1023. (Pubitemid 46621661)
24. Lamfers ML, Grill J, Dirven CM et al. Potential of the conditionally replicative adenovirus Ad5-Delta24RGD in the treatment of malignant gliomas and its enhanced effect with radiotherapy. Cancer Res 2002; 62: 5736-5742. (Pubitemid 35204729)
25. Raki M, Sarkioja M, Desmond RA et al. Oncolytic adenovirus Ad5/3-delta24 and chemotherapy for treatment of orthotopic ovarian cancer. Gynecol Oncol 2008; 108: 166-172. (Pubitemid 350299441)
26. Suzuki K, Alemany R, Yamamoto M, Curiel DT. The presence of the adenovirus E3 region improves the oncolytic potency of conditionally replicative adenoviruses. Clin Cancer Res 2002; 8: 3348-3359. (Pubitemid 35340708)
27. Bazan-Peregrino M, Carlisle RC, Hernandez-Alcoceba R et al. Comparison of molecular strategies for breast cancer virotherapy using oncolytic adenovirus. Hum Gene Ther 2008; 19: 873-886.
28. Libertini S, Iacuzzo I, Perruolo G et al. Bevacizumab increases viral distribution in human anaplastic thyroid carcinoma xenografts and enhances the effects of E1A-defective adenovirus d1922-947. Clin Cancer Res 2008; 14: 6505-6514.
29. Hallden G, Hill R, Wang Yet al. Novel immunocompetent murine tumor models for the assessment of replication-competent oncolytic adenovirus efficacy. Mol Ther 2003; 8: 412-424.
30. Cheong SC, Wang Y, Meng JH et al. E1A-expressing adenoviral E3B mutants act synergistically with chemotherapeutics in immunocompetent tumor models. Cancer Gene Ther 2008; 15: 40-50. (Pubitemid 350261299)
31. White E. Regulation of the cell cycle and apoptosis by the oncogenes of adenovirus. Oncogene 2001; 20: 7836-7846 (Pubitemid 33135310)
32. Subramanian T, Vijayalingam S, Chinnadurai G. Genetic identification of adenovirus type 5 genes that influence viral spread. J Virol 2006; 80: 2000-2012. (Pubitemid 43228740)
33. Yoon AR, Kim JH, Lee YS et al. Markedly enhanced cytolysis by E1B-19kD-deleted oncolytic adenovirus in combination with cisplatin. Hum Gene Ther 2006; 17: 379-390.
34. Liu TC, Hallden G, Wang Y et al. An E1B-19 kDa gene deletion mutant adenovirus demonstrates tumor necrosis factor-enhanced cancer selectivity and enhanced oncolytic potency. Mol Ther 2004; 9: 786-803. (Pubitemid 38878125)
35. Liu TC, Wang Y, Hallden G et al. Functional interactions of antiapoptotic proteins and tumor necrosis factor in the context of a replication-competent adenovirus. Gene Ther 2005; 12: 1333-1346. (Pubitemid 43084489)
36. White E. Mechanisms of apoptosis regulation by viral oncogenes in infection and tumorigenesis. Cell Death Differ 2006; 13: 1371-1377. (Pubitemid 44057472)
37. Cross JR, Postigo A, Blight K, Downward J. Viral pro-survival proteins block separate stages in Bax activation but changes in mitochondrial ultrastructure still occur. Cell Death Differ 2008; 15: 997-1008. (Pubitemid 351712604)
38. Sauthoff H, Heitner S, Rom WN, Hay JG. Deletion of the adenoviral E1b-19kD gene enhances tumor cell killing of a replicating adenoviral vector. Hum Gene Ther 2000; 11: 379-388. (Pubitemid 30101948)
39. Lomonosova E, Subramanian T, Chinnadurai G. Mitochondrial localization of p53 during adenovirus infection and regulation of its activity by E1B-19K. Oncogene 2005; 24: 6796-6808 (Pubitemid 41487038)
40. Charrier C, Degryse E, Gantzer M, Dieterle A, Pavirani A, Mehtali M. Efficient generation of recombinant adenovirus vectors by homologous recombination in Escherichia coli. J Virol 1996; 70: 4805-4810. (Pubitemid 26187479)
41. Leitner S, Sweeney K, Oberg D et al. Oncolytic Adenoviral Mutants with E1B19K Gene Deletions Enhance Gemcitabine-induced Apoptosis in Pancreatic Carcinoma Cells and Anti-Tumor Efficacy In vivo. Clin Cancer Res 2009; 15: 1730-1740.
42. Moore PS, Sipos B, Orlandini S et al. Genetic profile of 22 pancreatic carcinoma cell lines. Analysis of K-ras, p53, p16 and DPC4/Smad4. Virchows Arch 2001; 439: 798-802.
43. Skjoth IH, Issinger OG. Profiling of signaling molecules in four different human prostate carcinoma cell lines before and after induction of apoptosis. Int J Oncol 2006; 28: 217-229.